39
Participants
Start Date
January 31, 2016
Primary Completion Date
April 30, 2022
Study Completion Date
April 30, 2022
MLN9708
Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
Cytarabine
Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
Daunorubicin
Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
Massachusetts General Hospital, Boston
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Massachusetts General Hospital
OTHER